Cargando…
A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models
For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors. We hypothesized that a silicone based anti-estrogen-eluting implant pl...
Autores principales: | Thomas, Scott, Roche, Elysia, Desai, Pujan, Pawlowska, Nela, Bauer, Diana, Gingrich, David, Hsu, Emily, Deitchman, Amelia N., Aweeka, Fran, Munster, Pamela N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635313/ https://www.ncbi.nlm.nih.gov/pubmed/37961240 http://dx.doi.org/10.21203/rs.3.rs-3459372/v1 |
Ejemplares similares
-
Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019) -
Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023) -
Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004) -
The Risk of Treating Populations Instead of Patients
por: Deitchman, Amelia N.
Publicado: (2019) -
Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)